skip to main content

ProfessionalsKit Mak

Kit Mak
Counsel

Tel: +852-2846-0311
Fax: +852-2840-4300
kmak@paulweiss.com

+852-2846-0311
Hong Kong

Hong Kong Club Building, 12th Floor
3A Chater Road, Central
Hong Kong
Fax: +852-2840-4300

+ vCard ADD TO CONTACTS
Education 
Languages 
Bar Admissions 
Education 
Languages 
Bar Admissions 

Kit Mak is counsel in the Finance Group of the Corporate Department, based in our Hong Kong office. Kit’s practice is focused on complex cross-border financing, special situations and real estate transactions. He regularly advises private equity sponsors and their portfolio companies, financial institutions, Chinese policy banks, hedge funds, and corporate clients in acquisition finance, bilateral and syndicated lending, limited recourse and secured financings and restructuring transactions across the Asia Pacific region.

EXPERIENCE

Prior to joining Paul, Weiss, Kit was an associate in the finance department of an international law firm. He completed a secondment with SSG Capital Management (Hong Kong) Limited in 2014 as well as the real estate finance division of an international bank in 2015. Kit also worked for several years in London, Hong Kong, Beijing and Tokyo at another international law firm and was seconded to the Principal Investments division of an international bank in Hong Kong.

Prior to joining the firm, select transactions on which Kit has worked on recently include advising:

  • A regional private equity fund as mezzanine creditor in respect of its financing to a purchaser for the acquisition of a company that holds oil and gas interests in Indonesia;
  • A multinational asset manager on a loan transaction to an Indian group in the LED screen business in connection with its acquisitions in Australia and New Zealand;
  • Sun Hung Kai Investment Services Limited, a leading Asian investment management and advisory firm, as financier to the offeror in a mandatory unconditional offer for the issued shares and the outstanding convertible bonds of Asia Allied Infrastructure Holdings Limited (HKSE: 0711);
  • Sun Hung Kai Investment Services Limited, a leading Asian investment management and advisory firm, as financier to Ally Bridge Group (as a joint offeror with a consortium established by an affiliate of the target company’s controlling shareholder and GL Capital Group) in its proposed HK$2.34 billion (US$300 million) privatization offer for the H shares of Shandong Luoxin Pharmaceutical Group (HKSE: 8058) by way of a voluntary conditional cash offer;
  • An international bank in a HK$530 million limited recourse financing to a global private equity sponsor in its acquisition of a commercial property in Hong Kong;
  • An international bank in a US$105.5 million limited recourse financing to a global private equity sponsor in its acquisition of a commercial property in Shanghai;
  • A regional private equity fund in connection with its purchase of senior and unsecured debt of, and the majority equity stake in, a company holding a power plant project based in Thailand;
  • A global insurance company on structuring real estate investments across Asia;
  • A private equity fund and an investment bank on their exit from a PRC real estate development;
  • A global investment bank in its investment in senior, secured, rated and listed redeemable and non-convertible debentures issued by an Indian infrastructure developer;
  • A subscriber of US$140 million secured second lien convertible bonds and warrants privately placed by Singapore listed company that owns aluminum production assets in China;
  • Bain Capital:
    • on the financing for its leverage acquisition of Australian franchiser Retail Zoo; and
    • its portfolio company Bellsystem24 on the refinancing of the term and revolving credit facilities of Bellsystem24;
  • The Special Committee of ChinaEdu Corporation, a leading online educational services provider in China, in the take-private of ChinaEdu Corporation by its Executive Chairwoman and CEO; and
  • TPG on the term and revolving facilities for its leveraged acquisition and take-private of ShangPharma Corporation, a leading provider of contract research outsourcing services in China.

He is admitted to practice in Hong Kong, New York, England and Wales and is a non-practising Advocate and Solicitor in Singapore.

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy